Cite
HARVARD Citation
Lin, C. et al. (n.d.). 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. Journal for immunotherapy of cancer. p. A235. [Online].